Switzerland-based drugmaker Roche will invest 3 billion Swiss francs in the construction of a new research and development centre in Basel for around 1,900 employees, in a state-of-the-art office building for up to 1,700 employees, in upgrading infrastructure and in renovating the historic office building.
“Roche is committed long-term to Switzerland and to Basel in its dual role as corporate headquarters and one of our most important sites worldwide”, said Severin Schwan, Chief Executive Officer, Roche, explaining the rationale behind the plans. “The entire value chain is represented in Basel. Employees from all parts of the company are making a vital contribution to Roche’s innovative strength, and we want to provide them with an attractive work environment. The new buildings will continue Roche’s tradition of elegant, distinctive and functional architecture.”
EP News Bureau – Mumbai
